Id Biomedical Corporation of Quebec

The Council of the Queensland Institute of Medical Research

The Brigham and Women's Hospital, Inc.

David S Burt

Howard L Weiner

George H Lowell

David Hugh Jones

Clement Rioux

Dan Frenkel

Ruth Maron

Joseph J Zimmermann

Gregory Lee White

Kirkor Torossian

Louis F Fries, Iii

Martin Plante

Michael Good

Robert Anderson

Tomas B Leanderson

Michael R Batzloff

George L White

Yan Huang

David Jones

David H Jones

Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).

Compositions and methods for activating innate and allergic immunity

An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.

Proteosome-liposaccharide vaccine adjuvant

Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included.

Proteosome influenza vaccine

The present invention relates generally to methods of treating or preventing RSV infections, and more specifically, to compositions, and the use thereof, comprising one or more RSV G protein immunogen or fragment thereof capable of eliciting protective immunity without eliciting an immunopathological response or eliciting a reduced immunopathological response.

Subunit vaccine against respiratory syncytial virus infection

Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.

Vaccine

Growing community of inventors

Dollard des Ormeaux, Canada

David S Burt